{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:52:20Z","timestamp":1777679540871,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,15]]},"DOI":"10.7759\/cureus.105274","type":"journal-article","created":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T22:04:41Z","timestamp":1773612281000},"source":"Crossref","is-referenced-by-count":1,"title":["Gingival-Dominant Presentation of DPP-4 Inhibitor-Associated Bullous Pemphigoid: A Case Report"],"prefix":"10.7759","author":[{"given":"Yasuyuki","family":"Fujii","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chika","family":"Togashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moe","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Kawase-Koga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt E","year":"2013","unstructured":"Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013, 381:320-32. 10.1016\/s0140-6736(12)61140-4","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00220","article-title":"The growing incidence of bullous pemphigoid: overview and potential explanations","volume":"5","author":"Kridin K","year":"2018","unstructured":"Kridin K, Ludwig RJ. The growing incidence of bullous pemphigoid: overview and potential explanations. Front Med (Lausanne). 2018, 5:220. 10.3389\/fmed.2018.00220","journal-title":"Front Med (Lausanne)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.2352","article-title":"Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients","volume":"154","author":"Kridin K","year":"2018","unstructured":"Kridin K, Bergman R. Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients. JAMA Dermatol. 2018, 154:1152-8. 10.1001\/jamadermatol.2018.2352","journal-title":"JAMA Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.06.622","article-title":"Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid","volume":"136","author":"Izumi K","year":"2016","unstructured":"Izumi K, Nishie W, Mai Y, et al.. Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid. J Invest Dermatol. 2016, 136:2201-10. 10.1016\/j.jid.2016.06.622","journal-title":"J Invest Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16061","article-title":"Dipeptidyl peptidase 4 inhibitor-associated mucous membrane pemphigoid","volume":"48","author":"Suezawa M","year":"2021","unstructured":"Suezawa M, Dainichi T, Kaku Y, et al.. Dipeptidyl peptidase 4 inhibitor-associated mucous membrane pemphigoid. J Dermatol. 2021, 48:1584-7. 10.1111\/1346-8138.16061","journal-title":"J Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoms.2023.03.007","article-title":"Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid diagnosed by oral manifestation","volume":"35","author":"Yanai Y","year":"2023","unstructured":"Yanai Y, Kori Y, Fujimoto T, Imajo I, Yanai R, Yamada T. Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid diagnosed by oral manifestation. J Oral Maxillofac Surg Med Pathol. 2023, 35:528-33. 10.1016\/j.ajoms.2023.03.007","journal-title":"J Oral Maxillofac Surg Med Pathol"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajoms.2023.02.011","article-title":"Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid with oral mucosal lesions: a case report","volume":"35","author":"Iguchi N","year":"2023","unstructured":"Iguchi N, Minabe M, Akira Y, et al.. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid with oral mucosal lesions: a case report. J Oral Maxillofac Surg Med Pathol. 2023, 35:559-63.","journal-title":"J Oral Maxillofac Surg Med Pathol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12903-024-05109-5","article-title":"Efficacy of the injectable platelet-rich fibrin (i-PRF) in gingival phenotype modification: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Idris MI","year":"2024","unstructured":"Idris MI, Burhan AS, Hajeer MY, Sultan K, Nawaya FR. Efficacy of the injectable platelet-rich fibrin (i-PRF) in gingival phenotype modification: a systematic review and meta-analysis of randomized controlled trials. BMC Oral Health. 2024, 24:1331. 10.1186\/s12903-024-05109-5","journal-title":"BMC Oral Health"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.25104","article-title":"Evaluation of the hyaluronic acid versus the injectable platelet-rich fibrin in the management of the thin gingival phenotype: a split-mouth randomized controlled clinical trial","volume":"14","author":"Faour NH","year":"2022","unstructured":"Faour NH, Dayoub S, Hajeer MY. Evaluation of the hyaluronic acid versus the injectable platelet-rich fibrin in the management of the thin gingival phenotype: a split-mouth randomized controlled clinical trial. Cureus. 2022, 14:e25104. 10.7759\/cureus.25104","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0409","article-title":"Dipeptidyl peptidase 4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes","volume":"42","author":"Douros A","year":"2019","unstructured":"Douros A, Rouette J, Yin H, Yu OH, Filion KB, Azoulay L. Dipeptidyl peptidase 4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes. Diabetes Care. 2019, 42:1496-503. 10.2337\/dc19-0409","journal-title":"Diabetes Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.4556","article-title":"Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes","volume":"155","author":"Lee SG","year":"2019","unstructured":"Lee SG, Lee HJ, Yoon MS, Kim DH. Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes. JAMA Dermatol. 2019, 155:172-7. 10.1001\/jamadermatol.2018.4556","journal-title":"JAMA Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14004","article-title":"Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase-4 inhibitors: a population-based cohort study using Japanese Latter-Stage Elderly Healthcare Database","volume":"14","author":"Harano Y","year":"2023","unstructured":"Harano Y, Mitamura Y, Jiang P, Fujita T, Babazono A. Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase-4 inhibitors: a population-based cohort study using Japanese Latter-Stage Elderly Healthcare Database. J Diabetes Investig. 2023, 14:756-66. 10.1111\/jdi.14004","journal-title":"J Diabetes Investig"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14237","article-title":"Case of bullous pemphigoid associated with teneligliptin accompanied by severe mucous membrane involvement","volume":"45","author":"Kage Y","year":"2018","unstructured":"Kage Y, Yamaguchi Y, Uchida T, et al.. Case of bullous pemphigoid associated with teneligliptin accompanied by severe mucous membrane involvement. J Dermatol. 2018, 45:e205-6. 10.1111\/1346-8138.14237","journal-title":"J Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2015.10.012","article-title":"Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes","volume":"110","author":"Aso Y","year":"2015","unstructured":"Aso Y, Fukushima M, Sagara M, et al.. Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes. Diabetes Res Clin Pract. 2015, 110:250-6. 10.1016\/j.diabres.2015.10.012","journal-title":"Diabetes Res Clin Pract"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.3047","article-title":"Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication","volume":"8","author":"Shinohara Y","year":"2020","unstructured":"Shinohara Y, Iijima T, Sakurai S, et al.. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication. Clin Case Rep. 2020, 8:2007-12. 10.1002\/ccr3.3047","journal-title":"Clin Case Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18032","article-title":"The optimal oral biopsy site for diagnosis of mucous membrane pemphigoid and pemphigus vulgaris","volume":"182","author":"Carey B","year":"2020","unstructured":"Carey B, Joshi S, Abdelghani A, Mee J, Andiappan M, Setterfield J. The optimal oral biopsy site for diagnosis of mucous membrane pemphigoid and pemphigus vulgaris. Br J Dermatol. 2020, 182:747-53. 10.1111\/bjd.18032","journal-title":"Br J Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.3425","article-title":"Bullous pemphigoid severity and levels of antibodies to BP180 and BP230: a systematic review and meta-analysis","volume":"160","author":"Chou PY","year":"2024","unstructured":"Chou PY, Yu CL, Wen CN, Tu YK, Chi CC. Bullous pemphigoid severity and levels of antibodies to BP180 and BP230: a systematic review and meta-analysis. JAMA Dermatol. 2024, 160:1192-200. 10.1001\/jamadermatol.2024.3425","journal-title":"JAMA Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.12.038","article-title":"Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland","volume":"78","author":"Benzaquen M","year":"2018","unstructured":"Benzaquen M, Borradori L, Berbis P, Cazzaniga S, Valero R, Richard MA, Feldmeyer L. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland. J Am Acad Dermatol. 2018, 78:1090-6. 10.1016\/j.jaad.2017.12.038","journal-title":"J Am Acad Dermatol"},{"key":"ref19","doi-asserted-by":"crossref","DOI":"10.1001\/archderm.1994.01690060083010","article-title":"Nicotinamide and tetracycline therapy of bullous pemphigoid","volume":"130","author":"Fivenson DP","year":"1994","unstructured":"Fivenson DP, Breneman DL, Rosen GB, Hersh CS, Cardone S, Mutasim D. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol. 1994, 130:753-8.","journal-title":"Arch Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/472421-gingival-dominant-presentation-of-dpp-4-inhibitor-associated-bullous-pemphigoid-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T22:04:42Z","timestamp":1773612282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/472421-gingival-dominant-presentation-of-dpp-4-inhibitor-associated-bullous-pemphigoid-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,15]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.105274","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,15]]}}}